Is a complete TRAX research report available?

No complete published report is available for First Tracks Biotherapeutics, Inc. (TRAX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

First Tracks Biotherapeutics, Inc. (TRAX)

NASDAQ: TRAX · USD

$41.9

+0.02 (+0.1%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first TRAX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	1.5B
Net income (ttm)	-169.4M
EPS (ttm)	-$4.85
Shares out	34.9M
Volume	582,191
Price target	$50.8	+21.2%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -169.4M
EPS (ttm): -$4.85
Market cap: 1.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All TRAX indicators

Market & fundamental data

Available fields

142

Groups with data

Currency

USD

Showing 142 of 142 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0002091349
Company name	First Tracks Biotherapeutics, Inc.
Country	United States
Country code	US
Cusip	337185102
Employees	104
Enterprise value	$1.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US3371851029
Last refreshed	2026-07-30
Market cap	$1.5B
Market cap category	Small-Cap
Price	$41.87
Price currency	USD
Sector	Healthcare
Sector PE	45.63
Sector PE Fwd	24.38
Symbol	TRAX
Website	https://www.firsttracksbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-11.59%
FCF yield	-8.94%
P/B ratio	5.67x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-139.6M
Net Income	$-169.4M
Net Income Growth Years	0%
Profit Per Employee	$-1.6M
ROCE	-70.12

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$290.6M
Cash	$286.5M
Current Assets	$289.4M
Current Liabilities	$33.1M
Debt	$0
Equity	$257.5M
Liabilities	$33.1M
Long Term Assets	$1.2M
Long Term Liabilities	$0
Net Cash	$286.5M
Net Cash By Market Cap	$19.61
Net Debt Equity	$-1.11
Tangible Book Value	$257.5M
Tangible Book Value Per Share	$7.38

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.74
Net Working Capital	$-30.2M
Quick ratio	8.65
Working Capital	$256.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
50-day SMA	23.33
All Time High	46.45
All Time High Change	-9.86%
All Time High Date	2026-07-27
All Time Low	14.72
All Time Low Change	184.44%
All Time Low Date	2026-06-03
ATR	3.76
Beta1y	1.37
High	43.81
High52	46.45
High52 Date	2026-07-27
High52ch	-9.86%
Low	40.6
Low52	14.72
Low52 Date	2026-06-03
Low52ch	184.44%
Ma50ch	79.5%
Premarket Change Percent	-2.08
Premarket Price	$40.98
RSI	77.05
RSI Monthly	0
RSI Weekly	73.13
Sharpe ratio	2.3x
Sortino ratio	5.35
Tr1m	161.2%
Tr1w	9.69%
Tr3m	108.83%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	6
Analyst Price Target Top	$48.83
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Operating Income	$-180.5M
Price target	$50.75
Price Target Change	$21.21
Price Target Change Top	$16.62

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	30,223,174%
Float Percent	86.62%
Shares Insiders	1.93%
Shares Institutions	19.82%
Shares Out	34,892,381
Short Float	15.79%
Short Ratio	4.92
Short Shares	13.68

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-166.6M
Adjusted OCF	-166,538,000
Average Volume	992,972.15x
Bv Per Share	7.38
CAPEX	$-69,000
Ch1m	161.2
Ch1w	9.69
Ch3m	108.8
Change	0.05%
Change From Open	1.85
Close	41.85
Days Gap	-1.77
Depreciation Amortization	538,000
Dollar Volume	24,376,337.2
Earnings Date	2026-08-13
EBIT	$-180.5M
EBITDA	$-180M
EPS	$-4.85
F Score	1
FCF	$-130.6M
FCF EV Yield	-11.12x
FCF Per Share	$-3.74
Financing CF	32,145,000
Fiscal Year End	December
Founded	2,025
Investing CF	248,168,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-06-01
Last Report Date	2026-03-31
Last Split Type	Never
Ma20	32.83
Ma20ch	27.52%
Net CF	149,832,000
Next Earnings Date	2026-08-13
Open	41.11
Optionable	No
Position In Range	39.56
Ppne	1,174,000
Pre Close	41.85
Price Date	2026-07-29
Ptbv Ratio	5.67
Relative Volume	0.59x
Share Based Comp	36,057,000
Us State	California
Volume	582,191

First Tracks Biotherapeutics, Inc. (TRAX)

Coverage state: Market snapshot only — no published research

Generate the first TRAX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · TRAX

Valuation

Balance sheet

Trading

Next earnings

Sector percentile context

All TRAX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on TRAX

Frequently asked questions